Fampridine immediate-release

Drug Profile

Fampridine immediate-release

Alternative Names: 4-Aminopyridine immediate release; 4-AP - Neurorecovery; 4-AP IR; Ampydin IR; Fampridine IR

Latest Information Update: 12 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurorecovery
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Guillain-Barre syndrome

Highest Development Phases

  • Suspended Guillain-Barre syndrome

Most Recent Events

  • 22 Sep 2014 Biomarkers information updated
  • 12 Feb 2008 Suspended - Phase-II for Guillain-Barre syndrome in USA (PO)
  • 05 Feb 2008 Acorda Therapeutics acquires ownership of Neurorecovery's fampridine immediate-release product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top